Eastman Chemical Company
EMN
$65.31
+2.85%
Eastman Chemical Company is a global specialty chemicals manufacturer producing additives and functional products, advanced materials, chemical intermediates, and fibers for end markets spanning transportation, building and construction, consumables, and textiles, with the majority of sales generated outside the United States and a strong Asian footprint. Spun out of Eastman Kodak in 1994, the company has deliberately repositioned itself from a diversified commodity-levered chemical producer into a higher-margin specialty portfolio, divesting noncore assets and leaning on innovation-led product lines such as specialty plastics and circular-recycling technologies. The current investor debate centers on whether that specialty mix can deliver durable earnings through a soft industrial demand backdrop, with attention focused on the company's molecular-recycling platform as a potential multi-year growth catalyst against persistent volume pressure in chemical intermediates and fibers. Recent quarterly results showed revenue growth returning on a year-over-year basis, but margin compression and a heavily leveraged balance sheet have kept sentiment cautious, and the stock has materially underperformed the broader market over the trailing year.…
EMN
Eastman Chemical Company
$65.31
EMN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eastman Chemical Company's 12-month outlook, with a consensus price target around $75.06 and implied upside of +14.9% versus the current price.
Average Target
$75.06
0 analysts
Implied Upside
+14.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$65 - $85
Analyst target range
Sixteen analysts cover Eastman with a consensus recommendation of "buy" and a mean rating of 2.12 on a scale where lower is more bullish, indicating a moderately constructive stance. The average target price of $76.19 implies roughly 22.2% upside from the current $62.33, a meaningful gap that suggests the sell-side views the recent decline as overdone relative to fundamentals. Recent institutional actions support that view: Citigroup, UBS, and JP Morgan all maintain Buy or Overweight ratings, while Morgan Stanley reiterated Overweight in July 2026, though RBC Capital and Wells Fargo remain at Sector Perform and Equal Weight, respectively, reflecting a split between value-oriented bulls and more cautious neutral voices.
The target range of $65.00 to $87.00 is wide, spanning a 34% spread that signals meaningful disagreement about the earnings recovery path. The high target of $87.00, about 40% above the current price, would require multiple expansion toward the mid-teens forward PE alongside delivery of the $7.43 consensus EPS estimate, implying confidence in margin recovery and the circular-recycling growth story. The low target of $65.00, only 4.3% above the current price, prices in continued margin compression and weak industrial demand, essentially a no-recovery scenario. Notably, the low target sits above the current price, meaning even the most bearish analyst sees modest upside, which is a bullish signal at this valuation; however, the absence of any recent upgrades and the stock's persistent underperformance suggest the consensus target may be slow to adjust downward if the recovery fails to materialize.
Drowning in data?
Find the real signal!
Bulls vs Bears: EMN Investment Factors
The bear case currently holds stronger near-term evidence: EMN has fallen 15.52% over six months, lags the S&P 500 by 23 percentage points, and sits in the bottom quartile of its 52-week range with trailing EPS of just $0.065. However, the bull case rests on forward-looking data that is harder to dismiss — 9.88% revenue growth, sequential gross margin recovery from 17.13% to 22.28%, a 9.35x forward PE, and a unanimous analyst floor of $65.00 above the current price. The single most important tension is whether the $7.43 consensus EPS estimate is achievable: if margin recovery delivers even most of that figure, the stock is dramatically undervalued; if industrial demand stalls and estimates are cut, the 5.2% yield becomes a value trap. The technical downtrend argues for patience, but the valuation and analyst positioning argue that the risk/reward has shifted toward the upside for investors with a 12-month horizon.
Bullish
- Forward PE of 9.35x prices deep pessimism: At $62.33, EMN trades at just 9.35x forward EPS of $7.43 versus 15.46x trailing earnings, a 40% discount that embeds a substantial earnings recovery the market is not yet willing to pay for. For a specialty chemical company with 65% of revenue in higher-margin Advanced Materials and Additives segments, a single-digit forward multiple leaves limited room for further multiple compression.
- Analyst consensus sees 22% upside: Sixteen analysts carry a 'buy' consensus (mean rating 2.12) with an average target of $76.19, implying 22.2% upside from $62.33. Critically, even the lowest target of $65.00 sits 4.3% above the current price, meaning no covering analyst models a downside scenario from here.
- Revenue reaccelerating at 9.88% YoY: Q2 2026 revenue of $2.513 billion grew 9.88% over Q2 2025's $2.287 billion and rose sequentially from $2.177 billion in Q1 2026. The trajectory from $1.973 billion in Q4 2025 shows a clear upward inflection that supports the specialty-transformation thesis.
- Gross margin recovery underway: Gross margin expanded to 22.28% in Q2 2026 from 19.80% in Q1 2026 and 17.13% in Q4 2025, while net margin rebounded to 7.28% from 4.92% in Q1. This sequential improvement suggests input-cost relief and mix shift toward specialty products are beginning to flow through.
Bearish
- Earnings collapse: TTM EPS of $0.065: Trailing twelve-month EPS of just $0.065 and ROE of 7.95% reflect a severe earnings deterioration, with Q4 2025 net income of $105 million on a 5.32% margin and Q3 2025 EPS of only $0.41. The forward $7.43 consensus requires a more than 100-fold earnings rebound, an extraordinarily wide gap between current reality and expectations.
- Leverage and cash burn constrain flexibility: Debt-to-equity of 0.85x and a current ratio of 1.37 leave limited cushion, and Q1 2026 produced negative operating cash flow of -$137 million and free cash flow of -$240 million after a $444 million debt repayment. Interest expense of $56 million per quarter consumes roughly 18% of Q2 EBITDA of $442 million.
- Persistent relative underperformance: EMN has lagged SPY by 23.00% over six months, 11.83% over three months, and 11.92% over one year, while the S&P 500 gained 15.53%. With a beta of 1.076, this weakness is idiosyncratic rather than market-driven, and a short ratio of 5.73 days-to-cover shows bears remain entrenched.
- Margins below historical norms: TTM operating margin of 10.64% sits well below the mid-teens levels achieved in 2024, when Q4 2024 operating margin was 16.84% and Q1 2025 was 13.89%. Q2 2026 net margin of 7.28% still trails the 6.12% of Q2 2025 only marginally despite 9.88% higher revenue, showing poor operating leverage.
EMN Technical Analysis
Eastman is in a sustained downtrend that has erased most of its twelve-month gains, with the shares up just 3.61% over the past year but down 15.52% over six months and 9.14% over three months. At $62.33, the stock sits at roughly 22.9% of its 52-week range of $56.11 to $83.47, meaning it is trading in the bottom quartile of its annual band and only about 11% above its 52-week low. That positioning signals a falling-knife setup rather than a value opportunity: the stock has given back nearly all of its yearly advance and is pressing toward the lower boundary that has historically defined capitulation zones. The max drawdown of -23.67% over the period confirms a meaningful peak-to-trough decline rather than a shallow pullback.
Short-term momentum is decisively negative and accelerating to the downside, with the 1-month change of -4.21% and the 3-month change of -9.14% both confirming the longer-term downtrend rather than diverging from it. The most recent session saw a -2.41% decline on volume of about 1.76 million shares, and the stock has fallen from roughly $74 in mid-August to $62.33, a nearly 16% slide in two months that shows selling pressure intensifying into October. Relative strength is uniformly weak across every window: -5.43% versus SPY over one month, -11.83% over three months, -23.00% over six months, and -11.92% over one year, while the S&P 500 gained 15.53% over the trailing year. This persistent negative relative strength indicates the weakness is company- and sector-specific rather than a broad market drag, and the elevated short ratio of 5.73 days-to-cover suggests bears remain entrenched.
Key technical levels are well defined: support rests at the 52-week low of $56.11, roughly 10% below the current price, while resistance sits at the 52-week high of $83.47, about 34% above. A breakdown below $56.11 would signal a fresh leg lower and likely trigger momentum-driven selling, whereas reclaiming the $70-$74 congestion zone that capped rallies in August and September would be the first evidence of a trend reversal. The beta of 1.076 indicates the stock moves roughly in line with the market, so the underperformance is not explained by higher volatility but by idiosyncratic weakness; with a current price of $62.33 and a 52-week low of $56.11, position sizing should account for the risk of a retest of the annual low absent a catalyst.
Beta
1.08
1.08x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$56-$83
Price range past year
Annual Return
+6.7%
Cumulative gain past year
| Period | EMN Return | S&P 500 |
|---|---|---|
| 1m | -2.6% | -1.2% |
| 3m | -4.2% | +3.4% |
| 6m | -9.3% | +7.0% |
| 1y | +6.7% | +14.4% |
| ytd | +1.5% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMN Fundamental Analysis
Revenue is reaccelerating after a soft patch, with Q2 2026 sales of $2.513 billion representing 9.88% year-over-year growth versus $2.287 billion in Q2 2025. The sequential trajectory is constructive: revenue rose from $1.973 billion in Q4 2025 to $2.177 billion in Q1 2026 and $2.513 billion in Q2 2026, and the Q2 print also exceeded the $2.29 billion reported in Q1 2025. Segment data shows a balanced portfolio, with Advanced Materials at $817 million and Additives and Functional Products at $807 million together accounting for roughly 65% of the $2.51 billion total, while Chemical Intermediates at $643 million and Fibers at $243 million round out the mix. The growth trend supports the specialty-transformation thesis, but the 9.88% top-line gain has not translated into proportional profit growth, which is the central tension in the investment case.
Profitability is positive but under pressure. Q2 2026 net income of $183 million on $2.513 billion of revenue produced a 7.28% net margin, up from 4.92% in Q1 2026 but below the 6.12% recorded in Q2 2025 despite the higher revenue base. Gross margin of 22.28% in Q2 2026 was essentially flat versus 22.13% a year earlier but improved sharply from 19.80% in Q1 2026 and 17.13% in Q4 2025, suggesting input-cost relief and mix improvement are underway. Operating margin of 12.34% and EBITDA of $442 million (17.59% EBITDA margin) show the business remains solidly profitable, though the trailing twelve-month EPS of just $0.065 and ROE of 7.95% reflect the drag from weak prior quarters, and the 10.64% operating margin on a TTM basis sits below the mid-teens levels the company achieved in 2024.
Balance sheet leverage and cash generation are the key risk factors. Debt-to-equity stands at 0.85x with a current ratio of 1.37, and the Q1 2026 debt repayment of $444 million contributed to a working-capital-driven cash burn that produced negative operating cash flow of -$137 million and free cash flow of -$240 million in that quarter. The company recovered in Q2 2026 with operating cash flow of $224 million and free cash flow of $124 million, but TTM free cash flow of $539 million against a $7.32 billion market cap yields only about 7.4%, and the dividend consumes a substantial share of it, with a payout ratio of 80.4% and a 5.20% dividend yield. With capital expenditures running at roughly $100 million per quarter and interest expense of $56 million in Q2, internal cash generation covers obligations but leaves limited cushion, making the balance sheet sensitive to any demand downturn.
Quarterly Revenue
$2.5B
2026-06
Revenue YoY Growth
+9.9%
YoY Comparison
Gross Margin
22.3%
Latest Quarter
Free Cash Flow
$539000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMN Overvalued?
Because Eastman is profitable, the PE ratio is the appropriate primary metric. The stock trades at 15.46x trailing earnings but only 9.35x forward earnings, a 40% discount that implies the market expects a substantial earnings recovery, consistent with the consensus EPS estimate of $7.43 versus the depressed trailing figure. The forward multiple of 9.35x is low in absolute terms for a specialty chemical company, but the gap between trailing and forward PE reflects how far current earnings sit below normalized levels rather than an obvious mispricing.
Relative to the specialty chemicals sector, Eastman screens cheap on most measures. The price-to-sales ratio of 0.84x, price-to-book of 1.23x, and EV/EBITDA of 9.18x are all at or below typical sector levels, and the 5.20% dividend yield is well above the sector norm. The discount appears justified by inferior profitability: a 5.42% net margin and 10.64% operating margin are below what higher-quality specialty peers command, and ROE of 7.95% is modest. The market is pricing Eastman as a cyclical, leveraged specialty name rather than a premium franchise, and until margin recovery is demonstrated, the discount is likely to persist.
Historically, Eastman's valuation has compressed dramatically. The PE ratio stood at 38.4x in Q3 2025 and 20.3x in Q1 2026 before falling to 15.5x now, while the price-to-sales ratio has fallen from 4.49x in Q1 2025 to 0.84x today and price-to-book from 1.75x to 1.23x. The stock is near the bottom of its own multi-year valuation band, which historically has marked value opportunities, but the compression also reflects genuine fundamental deterioration in margins and returns rather than simple multiple de-rating. The 1.23x price-to-book is close to the lowest level in the dataset, suggesting limited downside from a book-value perspective but also signaling that the market does not expect returns on capital to improve quickly.
PE
15.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~20x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on leverage and cash-flow fragility. Debt-to-equity of 0.85x combines with quarterly interest expense of $56 million that absorbs roughly 18% of Q2 2026 EBITDA of $442 million, while Q1 2026 demonstrated how quickly cash generation can invert, producing -$137 million operating cash flow and -$240 million free cash flow after a $444 million debt repayment. The 80.4% payout ratio on a 5.20% dividend yield leaves thin coverage from TTM free cash flow of $539 million, meaning any demand downturn could force a choice between the dividend and deleveraging. Revenue concentration adds risk: Advanced Materials ($817 million) and Additives ($807 million) represent about 65% of the $2.51 billion quarterly total, tying results closely to transportation and construction cycles.
Market and competitive risks stem from the stock's persistent idiosyncratic weakness and valuation dynamics. With a beta of 1.076, EMN's 23.00% six-month underperformance versus SPY is not explained by market volatility but by company-specific deterioration, and the 5.73-day short ratio signals entrenched bearish positioning that can amplify declines. The 9.35x forward multiple is only cheap if the $7.43 EPS estimate holds; a single guidance cut would mechanically re-rate the stock higher on forward PE even as the price falls. Competitive pressure in chemical intermediates and fibers persists, and the molecular-recycling platform — the key multi-year growth narrative — has yet to prove it can scale commercially against larger rivals.
In a worst-case scenario, a weak Q3 print showing continued volume pressure in Chemical Intermediates and Fibers would trigger analyst estimate cuts, breaking the $65.00 low target and sending the stock to retest its 52-week low of $56.11 — a decline of roughly 10% from $62.33. A breakdown below that level, absent a catalyst, would open a fresh leg lower toward the -23.67% max drawdown magnitude applied from recent highs near $74, implying a potential 25-30% total drawdown from current levels in a prolonged industrial recession. The realistic downside band is therefore -10% to -25%, with the dividend yield providing only partial support given the stretched 80.4% payout ratio.
